Lixte Biotechnology Holdings, Inc. (LIXT) 10-Year Financial Performance & Capital Metrics

LIXT • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutLixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.Show more

Revenue $0
EBITDA -$4M +29.6%
Net Income -$4M +29.5%
EPS (Diluted) -1.59 +40.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -148.73% -33.9%
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 80 (top 20%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Shares diluted 17.4% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-3.33%

EPS CAGR

10Y-

5Y-

3Y-

TTM33.71%

ROCE

10Y Avg-279.49%

5Y Avg-122.2%

3Y Avg-128.71%

Latest-148.19%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	200K	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-1%	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	200K	0	0	0	0	0	0	0	0	0
Gross Margin %	1%	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-1%	-	-	-	-	-	-	-	-
Operating Expenses+	2.85M	2.13M	1.81M	2.14M	2.49M	3.27M	6.72M	6.31M	5.09M	3.57M
OpEx % of Revenue	14.23%	-	-	-	-	-	-	-	-	-
Selling, General & Admin	754.44K	833.78K	1.34M	2.1M	1.67M	2.04M	4.98M	4.96M	4.19M	2.85M
SG&A % of Revenue	3.77%	-	-	-	-	-	-	-	-	-
Research & Development	2.09M	1.3M	467.26K	40.7K	820.91K	1.22M	1.74M	1.35M	898.1K	726.23K
R&D % of Revenue	10.46%	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-2.65M	-2.13M	-1.81M	-2.14M	-2.49M	-3.27M	-6.72M	-6.31M	-5.09M	-3.57M
Operating Margin %	-13.23%	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.1%	0.19%	0.15%	-0.18%	-0.16%	-0.31%	-1.06%	0.06%	0.19%	0.3%
EBITDA+	-2.44M	0	0	0	-2.44M	0	-6.72M	-6.3M	-5.07M	-3.57M
EBITDA Margin %	-12.2%	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.2%	1%	-	-	-	1%	-	0.06%	0.2%	0.3%
D&A (Non-Cash Add-back)	205.77K	2.13M	1.81M	2.14M	0	3.27M	0	0	0	0
EBIT	-2.65M	-2.13M	-1.81M	-2.13M	-2.44M	-3.27M	-6.72M	-6.3M	-5.07M	-3.57M
Net Interest Income+	78	0	0	0	49.72K	1.56K	-6.79K	2.32K	1.25K	7.05K
Interest Income	78	183	1.38K	4.92K	49.72K	5.23K	626	11.2K	1.25K	7.05K
Interest Expense	0	183	1.38K	4.92K	0	3.67K	7.41K	8.88K	0	0
Other Income/Expense	-206K	183	1.38K	4.92K	49.72K	1.56K	-7.95K	-1.05K	3.21K	-13.18K
Pretax Income+	-2.85M	-2.13M	-1.81M	-2.13M	-2.44M	-3.26M	-6.73M	-6.31M	-5.09M	-3.59M
Pretax Margin %	-14.26%	-	-	-	-	-	-	-	-	-
Income Tax+	-78	-2.13K	-1.81K	-9.85K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-2.85M	-2.13M	-1.81M	-2.13M	-2.44M	-3.26M	-6.73M	-6.31M	-5.09M	-3.59M
Net Margin %	-14.26%	-	-	-	-	-	-	-	-	-
Net Income Growth %	-0.03%	0.25%	0.15%	-0.18%	-0.14%	-0.34%	-1.06%	0.06%	0.19%	0.3%
Net Income (Continuing)	-2.85M	-2.13M	-1.81M	-2.13M	-2.44M	-3.26M	-6.73M	-6.31M	-5.09M	-3.59M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-3.66	-2.68	-1.94	-2.18	-2.20	-2.89	-5.00	-4.00	-2.66	-1.59
EPS Growth %	0.02%	0.27%	0.28%	-0.12%	-0.01%	-0.31%	-0.73%	0.2%	0.34%	0.4%
EPS (Basic)	-3.60	-2.68	-1.94	-2.18	-2.20	-2.89	-5.00	-4.00	-2.66	-1.59
Diluted Shares Outstanding	779.89K	797.93K	930.29K	979.93K	1.12M	1.13M	1.35M	1.58M	1.92M	2.25M
Basic Shares Outstanding	779K	797K	930K	979.93K	1.12M	1.13M	1.35M	1.58M	1.91M	2.25M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	597.98K	433.41K	1.37M	4.33M	2.67M	5.23M	5.09M	5.56M	4.31M	1.04M
Cash & Short-Term Investments	129.38K	199.93K	1.31M	4.27M	2.6M	5.07M	4.82M	5.35M	4.2M	1.04M
Cash Only	25.28K	199.93K	1.31M	4.27M	2.6M	5.07M	4.82M	5.35M	4.2M	1.04M
Short-Term Investments	104.09K	0	0	0	0	0	0	0	0	0
Accounts Receivable	200K	0	0	0	14.37K	0	0	0	0	0
Days Sales Outstanding	365	-	-	-	-	-	-	-	-	-
Inventory	60.92K	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	62.32K	61.43K	24.29K	15K	150.24K	0	0	-106.55K
Total Non-Current Assets+	0	0	0	2.29K	0	76.9K	0	0	0	106.55K
Property, Plant & Equipment	0	0	0	0	0	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	2.29K	0	76.9K	0	0	0	106.55K
Total Assets+	597.98K	433.41K	1.37M	4.34M	2.67M	5.23M	5.09M	5.56M	4.31M	1.15M
Asset Turnover	0.33x	-	-	-	-	-	-	-	-	-
Asset Growth %	0.11%	-0.28%	2.16%	2.17%	-0.38%	0.96%	-0.03%	0.09%	-0.23%	-0.73%
Total Current Liabilities+	285.64K	218.65K	373.02K	210.91K	237.9K	216.52K	302.93K	395.76K	313.86K	318.28K
Accounts Payable	159.08K	159.59K	312.03K	195.21K	143.55K	190.29K	193.47K	183.75K	120.51K	83.21K
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	124.57K	59.06K	60.99K	15.7K	94.35K	15.77K	0	165.02K	157.1K	235.08K
Other Current Liabilities	0	0	60.99K	0	0	0	76.96K	0	0	0
Current Ratio	2.09x	1.98x	3.67x	20.55x	11.23x	24.15x	16.81x	14.05x	13.73x	3.26x
Quick Ratio	1.88x	1.98x	3.67x	20.55x	11.23x	24.15x	16.81x	14.05x	13.73x	3.26x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	0	0	0	0	0	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	285.64K	218.65K	373.02K	210.91K	237.9K	216.52K	302.93K	395.76K	313.86K	318.28K
Total Debt+	0	0	0	0	0	0	0	0	0	0
Net Debt	-25.28K	-199.93K	-1.31M	-4.27M	-2.6M	-5.07M	-4.82M	-5.35M	-4.2M	-1.04M
Debt / Equity	-	-	-	-	-	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-11666.20x	-1316.21x	-434.30x	-	-889.07x	-906.45x	-711.15x	-	-
Total Equity+	312.33K	214.76K	995.04K	4.13M	2.43M	5.01M	4.79M	5.17M	3.99M	827.22K
Equity Growth %	0.17%	-0.31%	3.63%	3.15%	-0.41%	1.06%	-0.04%	0.08%	-0.23%	-0.79%
Book Value per Share	0.40	0.27	1.07	4.21	2.18	4.44	3.56	3.26	2.08	0.37
Total Shareholders' Equity	312.33K	214.76K	995.04K	4.13M	2.43M	5.01M	4.79M	5.17M	3.99M	827.22K
Common Stock	4.79K	4.79K	5.8K	6.7K	6.7K	1.24K	1.37K	166	225	225
Retained Earnings	-18.57M	-20.71M	-22.52M	-24.65M	-27.09M	-30.35M	-37.08M	-43.39M	-48.48M	-52.07M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.18M	-1.68M	-1.41M	-1.51M	-1.67M	-2.13M	-4.14M	-4.61M	-4.29M	-3.16M
Operating CF Margin %	-10.91%	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.33%	0.23%	0.16%	-0.07%	-0.11%	-0.27%	-0.94%	-0.11%	0.07%	0.26%
Net Income	-2.85M	-2.13M	-1.81M	-2.13M	-2.44M	-3.26M	-6.73M	-6.31M	-5.09M	-3.59M
Depreciation & Amortization	0	0	0	0	0	0	0	0	0	0
Stock-Based Compensation	549.7K	287.16K	70.69K	785.61K	748.65K	1.25M	2.6M	0	773.2K	0
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	205.77K	87.16K	-81.74K	902.43K	0	0	0	1.55M	0	418.42K
Working Capital Changes	-84.49K	170.13K	325.54K	-163.52K	17.54K	-117.88K	-13.44K	154.76K	20.56K	3.01K
Change in Receivables	-200K	200K	0	0	-14.37K	14.37K	0	0	0	0
Change in Inventory	12.59K	35.12K	0	0	14.37K	0	0	0	0	0
Change in Payables	36.54K	519	152.44K	-116.82K	-51.66K	46.74K	35.67K	2.32K	0	-73.55K
Cash from Investing+	109.6K	104.09K	0	0	0	0	0	0	0	0
Capital Expenditures	0	0	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	109.6K	104	0	0	0	0	0	0	0	0
Cash from Financing+	2.05M	1.75M	2.52M	4.48M	0	4.6M	3.9M	5.14M	3.14M	0
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-2K	-2K	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	304.39K	0	18K	-21.7K	0	0	207.63K	0	6.32K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-2.18M	-1.68M	-1.41M	-1.51M	-1.67M	-2.13M	-4.14M	-4.61M	-4.29M	-3.16M
FCF Margin %	-10.91%	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.33%	0.23%	0.16%	-0.07%	-0.11%	-0.27%	-0.94%	-0.11%	0.07%	0.26%
FCF per Share	-2.80	-2.10	-1.52	-1.54	-1.50	-1.89	-3.07	-2.92	-2.24	-1.41
FCF Conversion (FCF/Net Income)	0.76x	0.79x	0.78x	0.71x	0.69x	0.65x	0.62x	0.73x	0.84x	0.88x
Interest Paid	0	0	0	0	0	3.67K	7.41K	0	16.23K	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-986.52%	-810%	-298.96%	-83.31%	-74.4%	-87.69%	-137.28%	-126.81%	-111.07%	-148.73%
Return on Invested Capital (ROIC)	-780.53%	-1060.8%	-	-	-	-	-	-	-	-
Gross Margin	100%	-	-	-	-	-	-	-	-	-
Net Margin	-1426%	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-11666.20x	-1316.21x	-434.30x	-	-889.07x	-906.45x	-711.15x	-	-
FCF Conversion	0.76x	0.79x	0.78x	0.71x	0.69x	0.65x	0.62x	0.73x	0.84x	0.88x
Revenue Growth	-	-100%	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Lixte Biotechnology Holdings, Inc. (LIXT) grew revenue by 0.0% over the past year. Growth has been modest.

Lixte Biotechnology Holdings, Inc. (LIXT) reported a net loss of $4.1M for fiscal year 2024.

Dividend & Returns

Lixte Biotechnology Holdings, Inc. (LIXT) has a return on equity (ROE) of -148.7%. Negative ROE indicates the company is unprofitable.

Lixte Biotechnology Holdings, Inc. (LIXT) had negative free cash flow of $2.6M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Lixte Biotechnology Holdings, Inc. (LIXT) 10-Year Financial Performance & Capital Metrics

LIXT • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

Revenue $0
EBITDA -$4M +29.6%
Net Income -$4M +29.5%
EPS (Diluted) -1.59 +40.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -148.73% -33.9%
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 80 (top 20%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Shares diluted 17.4% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-3.33%

EPS CAGR

10Y-

5Y-

3Y-

TTM33.71%

ROCE

10Y Avg-279.49%

5Y Avg-122.2%

3Y Avg-128.71%

Latest-148.19%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	200K	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-1%	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	200K	0	0	0	0	0	0	0	0	0
Gross Margin %	1%	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-1%	-	-	-	-	-	-	-	-
Operating Expenses+	2.85M	2.13M	1.81M	2.14M	2.49M	3.27M	6.72M	6.31M	5.09M	3.57M
OpEx % of Revenue	14.23%	-	-	-	-	-	-	-	-	-
Selling, General & Admin	754.44K	833.78K	1.34M	2.1M	1.67M	2.04M	4.98M	4.96M	4.19M	2.85M
SG&A % of Revenue	3.77%	-	-	-	-	-	-	-	-	-
Research & Development	2.09M	1.3M	467.26K	40.7K	820.91K	1.22M	1.74M	1.35M	898.1K	726.23K
R&D % of Revenue	10.46%	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-2.65M	-2.13M	-1.81M	-2.14M	-2.49M	-3.27M	-6.72M	-6.31M	-5.09M	-3.57M
Operating Margin %	-13.23%	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.1%	0.19%	0.15%	-0.18%	-0.16%	-0.31%	-1.06%	0.06%	0.19%	0.3%
EBITDA+	-2.44M	0	0	0	-2.44M	0	-6.72M	-6.3M	-5.07M	-3.57M
EBITDA Margin %	-12.2%	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.2%	1%	-	-	-	1%	-	0.06%	0.2%	0.3%
D&A (Non-Cash Add-back)	205.77K	2.13M	1.81M	2.14M	0	3.27M	0	0	0	0
EBIT	-2.65M	-2.13M	-1.81M	-2.13M	-2.44M	-3.27M	-6.72M	-6.3M	-5.07M	-3.57M
Net Interest Income+	78	0	0	0	49.72K	1.56K	-6.79K	2.32K	1.25K	7.05K
Interest Income	78	183	1.38K	4.92K	49.72K	5.23K	626	11.2K	1.25K	7.05K
Interest Expense	0	183	1.38K	4.92K	0	3.67K	7.41K	8.88K	0	0
Other Income/Expense	-206K	183	1.38K	4.92K	49.72K	1.56K	-7.95K	-1.05K	3.21K	-13.18K
Pretax Income+	-2.85M	-2.13M	-1.81M	-2.13M	-2.44M	-3.26M	-6.73M	-6.31M	-5.09M	-3.59M
Pretax Margin %	-14.26%	-	-	-	-	-	-	-	-	-
Income Tax+	-78	-2.13K	-1.81K	-9.85K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-2.85M	-2.13M	-1.81M	-2.13M	-2.44M	-3.26M	-6.73M	-6.31M	-5.09M	-3.59M
Net Margin %	-14.26%	-	-	-	-	-	-	-	-	-
Net Income Growth %	-0.03%	0.25%	0.15%	-0.18%	-0.14%	-0.34%	-1.06%	0.06%	0.19%	0.3%
Net Income (Continuing)	-2.85M	-2.13M	-1.81M	-2.13M	-2.44M	-3.26M	-6.73M	-6.31M	-5.09M	-3.59M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-3.66	-2.68	-1.94	-2.18	-2.20	-2.89	-5.00	-4.00	-2.66	-1.59
EPS Growth %	0.02%	0.27%	0.28%	-0.12%	-0.01%	-0.31%	-0.73%	0.2%	0.34%	0.4%
EPS (Basic)	-3.60	-2.68	-1.94	-2.18	-2.20	-2.89	-5.00	-4.00	-2.66	-1.59
Diluted Shares Outstanding	779.89K	797.93K	930.29K	979.93K	1.12M	1.13M	1.35M	1.58M	1.92M	2.25M
Basic Shares Outstanding	779K	797K	930K	979.93K	1.12M	1.13M	1.35M	1.58M	1.91M	2.25M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	597.98K	433.41K	1.37M	4.33M	2.67M	5.23M	5.09M	5.56M	4.31M	1.04M
Cash & Short-Term Investments	129.38K	199.93K	1.31M	4.27M	2.6M	5.07M	4.82M	5.35M	4.2M	1.04M
Cash Only	25.28K	199.93K	1.31M	4.27M	2.6M	5.07M	4.82M	5.35M	4.2M	1.04M
Short-Term Investments	104.09K	0	0	0	0	0	0	0	0	0
Accounts Receivable	200K	0	0	0	14.37K	0	0	0	0	0
Days Sales Outstanding	365	-	-	-	-	-	-	-	-	-
Inventory	60.92K	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	62.32K	61.43K	24.29K	15K	150.24K	0	0	-106.55K
Total Non-Current Assets+	0	0	0	2.29K	0	76.9K	0	0	0	106.55K
Property, Plant & Equipment	0	0	0	0	0	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	2.29K	0	76.9K	0	0	0	106.55K
Total Assets+	597.98K	433.41K	1.37M	4.34M	2.67M	5.23M	5.09M	5.56M	4.31M	1.15M
Asset Turnover	0.33x	-	-	-	-	-	-	-	-	-
Asset Growth %	0.11%	-0.28%	2.16%	2.17%	-0.38%	0.96%	-0.03%	0.09%	-0.23%	-0.73%
Total Current Liabilities+	285.64K	218.65K	373.02K	210.91K	237.9K	216.52K	302.93K	395.76K	313.86K	318.28K
Accounts Payable	159.08K	159.59K	312.03K	195.21K	143.55K	190.29K	193.47K	183.75K	120.51K	83.21K
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	124.57K	59.06K	60.99K	15.7K	94.35K	15.77K	0	165.02K	157.1K	235.08K
Other Current Liabilities	0	0	60.99K	0	0	0	76.96K	0	0	0
Current Ratio	2.09x	1.98x	3.67x	20.55x	11.23x	24.15x	16.81x	14.05x	13.73x	3.26x
Quick Ratio	1.88x	1.98x	3.67x	20.55x	11.23x	24.15x	16.81x	14.05x	13.73x	3.26x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	0	0	0	0	0	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	285.64K	218.65K	373.02K	210.91K	237.9K	216.52K	302.93K	395.76K	313.86K	318.28K
Total Debt+	0	0	0	0	0	0	0	0	0	0
Net Debt	-25.28K	-199.93K	-1.31M	-4.27M	-2.6M	-5.07M	-4.82M	-5.35M	-4.2M	-1.04M
Debt / Equity	-	-	-	-	-	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-11666.20x	-1316.21x	-434.30x	-	-889.07x	-906.45x	-711.15x	-	-
Total Equity+	312.33K	214.76K	995.04K	4.13M	2.43M	5.01M	4.79M	5.17M	3.99M	827.22K
Equity Growth %	0.17%	-0.31%	3.63%	3.15%	-0.41%	1.06%	-0.04%	0.08%	-0.23%	-0.79%
Book Value per Share	0.40	0.27	1.07	4.21	2.18	4.44	3.56	3.26	2.08	0.37
Total Shareholders' Equity	312.33K	214.76K	995.04K	4.13M	2.43M	5.01M	4.79M	5.17M	3.99M	827.22K
Common Stock	4.79K	4.79K	5.8K	6.7K	6.7K	1.24K	1.37K	166	225	225
Retained Earnings	-18.57M	-20.71M	-22.52M	-24.65M	-27.09M	-30.35M	-37.08M	-43.39M	-48.48M	-52.07M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.18M	-1.68M	-1.41M	-1.51M	-1.67M	-2.13M	-4.14M	-4.61M	-4.29M	-3.16M
Operating CF Margin %	-10.91%	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.33%	0.23%	0.16%	-0.07%	-0.11%	-0.27%	-0.94%	-0.11%	0.07%	0.26%
Net Income	-2.85M	-2.13M	-1.81M	-2.13M	-2.44M	-3.26M	-6.73M	-6.31M	-5.09M	-3.59M
Depreciation & Amortization	0	0	0	0	0	0	0	0	0	0
Stock-Based Compensation	549.7K	287.16K	70.69K	785.61K	748.65K	1.25M	2.6M	0	773.2K	0
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	205.77K	87.16K	-81.74K	902.43K	0	0	0	1.55M	0	418.42K
Working Capital Changes	-84.49K	170.13K	325.54K	-163.52K	17.54K	-117.88K	-13.44K	154.76K	20.56K	3.01K
Change in Receivables	-200K	200K	0	0	-14.37K	14.37K	0	0	0	0
Change in Inventory	12.59K	35.12K	0	0	14.37K	0	0	0	0	0
Change in Payables	36.54K	519	152.44K	-116.82K	-51.66K	46.74K	35.67K	2.32K	0	-73.55K
Cash from Investing+	109.6K	104.09K	0	0	0	0	0	0	0	0
Capital Expenditures	0	0	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	109.6K	104	0	0	0	0	0	0	0	0
Cash from Financing+	2.05M	1.75M	2.52M	4.48M	0	4.6M	3.9M	5.14M	3.14M	0
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-2K	-2K	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	304.39K	0	18K	-21.7K	0	0	207.63K	0	6.32K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-2.18M	-1.68M	-1.41M	-1.51M	-1.67M	-2.13M	-4.14M	-4.61M	-4.29M	-3.16M
FCF Margin %	-10.91%	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.33%	0.23%	0.16%	-0.07%	-0.11%	-0.27%	-0.94%	-0.11%	0.07%	0.26%
FCF per Share	-2.80	-2.10	-1.52	-1.54	-1.50	-1.89	-3.07	-2.92	-2.24	-1.41
FCF Conversion (FCF/Net Income)	0.76x	0.79x	0.78x	0.71x	0.69x	0.65x	0.62x	0.73x	0.84x	0.88x
Interest Paid	0	0	0	0	0	3.67K	7.41K	0	16.23K	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-986.52%	-810%	-298.96%	-83.31%	-74.4%	-87.69%	-137.28%	-126.81%	-111.07%	-148.73%
Return on Invested Capital (ROIC)	-780.53%	-1060.8%	-	-	-	-	-	-	-	-
Gross Margin	100%	-	-	-	-	-	-	-	-	-
Net Margin	-1426%	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-11666.20x	-1316.21x	-434.30x	-	-889.07x	-906.45x	-711.15x	-	-
FCF Conversion	0.76x	0.79x	0.78x	0.71x	0.69x	0.65x	0.62x	0.73x	0.84x	0.88x
Revenue Growth	-	-100%	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Lixte Biotechnology Holdings, Inc. (LIXT) grew revenue by 0.0% over the past year. Growth has been modest.

Lixte Biotechnology Holdings, Inc. (LIXT) reported a net loss of $4.1M for fiscal year 2024.

Dividend & Returns

Lixte Biotechnology Holdings, Inc. (LIXT) has a return on equity (ROE) of -148.7%. Negative ROE indicates the company is unprofitable.

Lixte Biotechnology Holdings, Inc. (LIXT) had negative free cash flow of $2.6M in fiscal year 2024, likely due to heavy capital investments.